Financial reports
10-Q
2024 Q2
Quarterly report
8 Aug 24
10-Q
2024 Q1
Quarterly report
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10 Oct 24
8-K
Regulation FD Disclosure
7 Oct 24
8-K
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
8 Aug 24
8-K
Material Modifications to Rights of Security Holders
28 Jun 24
8-K
Regulation FD Disclosure
24 Jun 24
8-K
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
3 Jun 24
8-K
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
22 May 24
8-K
Entry into a Material Definitive Agreement
14 May 24
8-K
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
7 May 24
8-K
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
19 Mar 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
9 Oct 24
FWP
Free writing prospectus
8 Oct 24
424B5
Prospectus supplement for primary offering
7 Oct 24
S-3ASR
Automatic shelf registration
7 Oct 24
S-8
Registration of securities for employees
19 Mar 24
424B5
Prospectus supplement for primary offering
12 Oct 23
424B5
Prospectus supplement for primary offering
11 Oct 23
S-8
Registration of securities for employees
7 Mar 23
S-3
Shelf registration
14 Nov 22
S-8
Registration of securities for employees
14 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
17 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
DEF 14A
Definitive proxy
15 Apr 21
DEF 14A
Definitive proxy
23 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
Other
EFFECT
Notice of effectiveness
28 Nov 22
CORRESP
Correspondence with SEC
22 Nov 22
UPLOAD
Letter from SEC
21 Nov 22
EFFECT
Notice of effectiveness
14 Apr 22
EFFECT
Notice of effectiveness
11 Jun 19
CT ORDER
Confidential treatment order
6 Jun 19
CORRESP
Correspondence with SEC
6 Jun 19
UPLOAD
Letter from SEC
6 Jun 19
CT ORDER
Confidential treatment order
4 Mar 19
EFFECT
Notice of effectiveness
24 May 18
Ownership
SC 13G/A
VANGUARD GROUP INC
4 Nov 24
4
Edward H Myles
10 Oct 24
4
Edward H Myles
7 Oct 24
4
Tracey Sacco
7 Oct 24
SC 13D/A
Samsara BioCapital, L.P.
7 Oct 24
4
SRINIVAS AKKARAJU
7 Oct 24
4
Jing L. Marantz
7 Oct 24
144
Notice of proposed sale of securities
7 Oct 24
144
Notice of proposed sale of securities
7 Oct 24
144
Notice of proposed sale of securities
7 Oct 24